FEDERAL COURT OF AUSTRALIA
Novartis AG v Pharmacor Pty Limited [2025] FCAFC 33
Appeal from: Novartis AG v Pharmacor Pty Limited (No 3) [2024] FCA 1307 File number(s): NSD 1811 of 2024 Judgment of: BURLEY, ROFE AND DOWNES JJ Date of judgment: 19 March 2025 Date of publication of reasons: 24 March 2025 Catchwords: PATENTS – infringement – standard patent for a pharmaceutical composition containing certain active pharmaceutical ingredients – claim construction – whether primary judge erred in construction of claim as not including a pharmaceutical composition where the active pharmaceutical ingredient is in the form of a complex in which the ions are associated by non-covalent bonds – no error shown
PATENTS – extension of patent term – appeal against primary judge’s finding that the extension of term was not validly granted – s 70 Patents Act 1990 (Cth) – no error shown
Legislation: Patents Act 1990 (Cth) ss 40(3), 70, 70(2)(a) Division: General Division Registry: New South Wales National Practice Area: Intellectual Property Sub-area: Patents and associated Statutes Number of paragraphs: 54 Date of hearing: 18-19 March 2025 Counsel for the Appellants: Mr T Cordiner KC and Mr B Mee Solicitor for the Appellants: Clayton Utz Counsel for the Respondent: Mr J Cooke SC and Mr D Larish Solicitor for the Respondent: Ashurst ORDERS
NSD 1811 of 2024 BETWEEN: NOVARTIS AG
First Appellant
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED (ACN 004 244 162)
Second Appellant
AND: PHARMACOR PTY LIMITED (ACN 121 020 835)
Respondent
AND BETWEEN: PHARMACOR PTY LIMITED (ACN 121 020 835)
Cross-Appellant
AND: NOVARTIS AG (and another named in the Schedule)
First Cross-Respondent
ORDER MADE BY:
BURLEY, ROFE AND DOWNES JJ
DATE OF ORDER:
19 MARCH 2025
THE COURT ORDERS THAT:
1.The appeal be dismissed.
2.The cross-appeal be dismissed.
3.The interlocutory application filed by the appellants on 16 December 2024 be dismissed with costs.
4.The appellants pay the respondent’s costs of the appeal and the cross-appeal.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
REASONS FOR JUDGMENT
INTRODUCTION
[1]
CONSTRUCTION
[12]
Claim 1
[12]
The primary judge’s reasoning in relation to construction
[13]
The construction appeal
[31]
INFRINGEMENT
[53]
PATENT TERM EXTENSION
[54]
THE COURT:
INTRODUCTION
This is an appeal from the decision of Novartis AG v Pharmacor Pty Limited (No 3) [2024] FCA 1307 (J). The appeal was brought on for an expedited hearing for reasons which are explained below.
The primary issue on the appeal concerned the construction of claim 1 of patent No. 2003206738 entitled “Pharmaceutical compositions comprising valsartan and NEP inhibitors”.
The appellants, Novartis AG and Novartis Pharmaceuticals Australia Pty Ltd (together, Novartis) contended that the primary judge erred in his construction of the claim and in failing to find that the respondent, Pharmacor Pty Limited, had threatened to engage in acts of infringement of that claim by signalling its intention to supply in Australia pharmaceutical products entered on the Australian Register of Therapeutic Goods (ARTG) identified in the…
Keep reading for free
Create a free CaseChat account to read Novartis AG v Pharmacor Pty Limited and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2025] FCAFC 33
- Decision Date
CaseChat Overview and Summary
The legal issues that the court had to decide included whether the primary judge had erred in the construction of a claim of the patent. Specifically, it was questioned whether the claim included a pharmaceutical composition where the active pharmaceutical ingredient was in the form of a complex in which the ions were associated by non-covalent bonds. The court also had to determine if there was an error in the primary judge’s finding that the extension of the patent term was not validly granted under section 70 of the Patents Act 1990 (Cth).
The court found that no error had been demonstrated in the primary judge's construction of the patent claim. The court reasoned that the claim did not encompass a pharmaceutical composition where the active pharmaceutical ingredient was in the form of a complex in which the ions were associated by non-covalent bonds. Additionally, the court held that there was no error in the primary judge’s determination that the extension of the patent term was not validly granted, as required by section 70 of the Patents Act 1990 (Cth). Therefore, the appeal and the cross-appeal were dismissed. Furthermore, the interlocutory application filed by the appellants was dismissed with costs. The appellants were ordered to pay the respondent’s costs of the appeal and the cross-appeal.
Orders
Orders of the court
1. The appeal be dismissed.
2. The cross-appeal be dismissed.
3. The interlocutory application filed by the appellants on 16 December 2024 be dismissed with costs.
4. The appellants pay the respondent’s costs of the appeal and the cross-appeal.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi